-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 5th, Gilead Sciences announced its "first-in-class" antibody-conjugated drug (ADC) Trodelvy (sacituzumab govitecan-hziy) at the ASCO annual meeting.
Trodelvy also extended the patient's overall survival to 10.
It is worth mentioning that Everest Medicines owns the development rights of this innovative antibody conjugate drug in Greater China.
TNBC is an aggressive breast cancer, accounting for about 15% of all breast cancers.
Trodelvy is a "first-in-class" antibody conjugate drug made by coupling a topoisomerase inhibitor with a monoclonal antibody targeting the Trop-2 receptor.
"Because many patients have rapid disease progression after receiving chemotherapy, the efficacy of Trodelvy as a second-line therapy for metastatic patients is of great significance.